5 Highest Yielding Dividend Stocks in the S&P 500
The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants.
Alexandria Real Estate: I'm Buying The Post-Earnings Plunge
Alexandria Real Estate (ARE) shares have plunged, creating a potential buying opportunity, as the stock appears deeply oversold after a capitulation-like selloff. ARE faces challenges including oversupply of lab space, weak biotech IPO market, and concerns over a possible dividend cut, but its payout ratio remains reasonable. The REIT offers a nearly 10% dividend yield, trades at a low valuation, and could benefit from future interest rate cuts and renewed biotech demand.
Alexandria Real Estate: Earnings Reaction Creates A Buying Opportunity
Alexandria Real Estate Equities, Inc. is rated a Strong Buy, offering a rare opportunity to acquire a high-quality REIT at a bargain price. ARE's recent 24% price drop is seen as overdone, with recovery expected as oversupply is repurposed and interest rates decline by 2026-2027. Projected FFO/share growth and multiple expansion could drive ARE to $143 by 2030, delivering a 143% gain plus an 8.4% dividend yield.
Alexandria Real Estate Equities, Inc. (ARE) Q3 2025 Earnings Call Transcript
Alexandria Real Estate Equities, Inc. (NYSE:ARE ) Q3 2025 Earnings Call October 28, 2025 2:00 PM EDT Company Participants Joel Marcus - Founder & Executive Chairman Marc Binda - CFO & Treasurer Peter M. Moglia - CEO & Chief Investment Officer Hallie Kuhn - Senior Vice President of Science & Technology and Capital Markets Conference Call Participants Paula Schwartz - Rx Communications Group LLC Farrell Granath - BofA Securities, Research Division Nicholas Joseph - Citigroup Inc., Research Division Richard Anderson - Cantor Fitzgerald & Co., Research Division Anthony Paolone - JPMorgan Chase & Co, Research Division Wesley Golladay - Robert W.
Alexandria Real Estate: Oversupply Torpedoes Guidance
On our previous coverage, we highlighted the big problems that Alexandria REIT faced. The miss this morning validates the thesis. There is a secular trend in place now and we are still not interested in buying.
Alexandria's Q3 AFFO & Revenues Miss Estimates, '25 View Narrowed
ARE's Q3 miss, lower occupancy and rising interest costs drag results, prompting a 2025 FFO guidance cut.
Alexandria Real Estate Equities (ARE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Alexandria Real Estate Equities (ARE) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alexandria Real Estate Equities (ARE) Lags Q3 FFO and Revenue Estimates
Alexandria Real Estate Equities (ARE) came out with quarterly funds from operations (FFO) of $2.22 per share, missing the Zacks Consensus Estimate of $2.31 per share. This compares to FFO of $2.37 per share a year ago.
More Rate Cuts Are Coming: Grab 6% High-Yield S&P 500 Stocks Now
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
Alexandria to Post Q3 Earnings: What to Expect From the Stock?
ARE's Q3 results may show lower revenues and FFO as occupancy pressures weigh on performance.
Alexandria Real Estate Equities Is A Great Prospect Despite Real Challenges
Alexandria Real Estate Equities remains a "Strong Buy" due to its attractive valuation and strategic position in the life sciences REIT sector. ARE is actively recycling its portfolio, selling non-revenue assets and reinvesting proceeds to reduce debt and fund new developments, despite recent revenue and profit declines. The company's megacampus strategy and focus on life sciences position it for long-term growth, even as sector vacancy rates and industry headwinds persist.
The Real Catalyst Behind Alexandria Real Estate
Alexandria Real Estate generated an 11% return in Q3. It may be starting to turn around its performance. With a 6.3% yield, a 57% payout ratio, and solid AFFO, ARE's dividend security stands out among healthcare REITs despite sector headwinds. I analyzed a catalyst that investors sometimes forget about in ARE: the potential of Big Pharma and Big Biotech.
